Preparation and characterization of Δ9- tetrahydrocannabinol-loaded biodegradable polymeric microparticles and their antitumoral efficacy on cancer cell lines

Journal of Drug Targeting

Volumn 21, Issue 8, 2013, Pages 710-718

  De La Ossa, Dolores Hernán Pérez ^a   Gil Alegre, Maria Esther ^a   Ligresti, Alessia ^b   Aberturas, María Del Rosario ^c   Molpeceres, Jesús ^c   Torres, Ana Isabel ^c   Di Marzo, Vincenzo ^b  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b Institute of Biomolecular Chemistry   (Italy)

^c UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

9 Tetrahydrocannabinol; Cancer; Cannabinoids; Drug delivery; Microencapsulation

Indexed keywords

ALPHA TOCOPHEROL; DICHLOROMETHANE; DISODIUM HYDROGEN PHOSPHATE; DRONABINOL; MICROSPHERE; POLYCAPROLACTONE; POLYMER; POLYSORBATE 80; POLYVINYL ALCOHOL; POTASSIUM DIHYDROGEN PHOSPHATE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; EMULSION; IN VITRO STUDY; MICROENCAPSULATION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; REVIEW; SUSTAINED DRUG RELEASE;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; CACO-2 CELLS; CELL LINE, TUMOR; CELL PROLIFERATION; DRONABINOL; DRUG DELIVERY SYSTEMS; EMULSIONS; HUMANS; MICROSPHERES; PARTICLE SIZE; POLYMERS; RATS; SOLVENTS;

EID: 84883221820     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2013.809089     Document Type: Review

References (44)

1. Mechoulam R, Peters M, Murillo-Rodriguez E, et al. Cannabidiol - recent advances. Chem Biodivers 2007;4: 1678-92. (Pubitemid 47377200)
2. Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: D9-tetrahydrocannabinol, cannabidiol and D9- tetrahydrocannabivarin. Br J Pharmacol 2008;153: 199-215.
3. Izzo AA, Borrelli F, Capasso R, et al. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci 2009;30: 515-27.
4. Pertwee RG. Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol 2009;156: 397-411.
5. Guzmán M. Cannabinoids: potential anticancer agents. Nat Rev Cancer 2003;3: 745-55. (Pubitemid 37328813)
6. Ben Amar M. Cannabinoids in medicine: a review of their therapeutic potential. J Ethnopharmacol 2006;105: 1-25.
7. Hanuš LO. Pharmacological and therapeutic secrets of plant and brain (endo)cannabinoids. Med Res Rev 2009;29: 213-71.
8. Parolaro D, Massi P. Cannabinoids as potential new therapy for the treatment of gliomas. Expert Rev Neurother 2008;8: 37-49.
9. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 2003;42: 327-60. (Pubitemid 36433875)
10. Ohlsson A, Lindgren JE, Andersson S, et al. Single-dose kinetics of deuterium-labelled cannabidiol in man after intravenous administration and smoking. Biomed Environ Mass Spectrom 1986;149: 495-9.
11. Mannila J, Ja?rvinen T, Ja?rvinen K, et al. Precipitation complexation method produces cannabidiol/beta-cyclodextrin inclusion complex suitable for sublingual administration of cannabidiol. J Pharm Sci 2007;96: 312-19. (Pubitemid 46363562)
12. Doyle E, Spence AA. Cannabis as a medicine? Br J Anaesth 1995; 74: 359-61.
13. Mattes RDShaw LM, Edling-Owens J, et al. Bypassing the firstpass effect for the therapeutic use of cannabinoids. Pharmacol Biochem Behav 1993;44: 745-7.
14. Hazekamp A, Verpoorte R. Structure elucidation of the tetrahydrocannabinol complex with randomly methylated [beta]-cyclodextrin. Eur J Pharm Sci 2006;29: 340-7. (Pubitemid 44709854)
15. Ohlsson A, Lindgren JE, Wahlen A, et al. Plasma delta-9- tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clin Pharmacol Ther 1980;28: 409-16. (Pubitemid 10007024)
16. Garrett ER, Tsau J. Stability of tetrahydrocannabinols I. J Pharm Sci 1974;63: 1563-74.
17. Grotenhermen F. Cannabinoids for therapeutic use. Designing systems to increase efficacy and reliability. Am J Drug Deliv 2004; 24: 229-40. (Pubitemid 40050867)
18. Thomas BF, Compton DR, Martin BR. Characterization of the lipophilicity of natural and synthetic analogs of delta 9-tetrahydrocannabinol and its relationship to pharmacological potency. J Pharmacol Exp Ther 1990;255: 624-30.
19. van Drooge D-J, Hinrichs WLJ, Dickhoff BHJ, et al. Spray freeze drying to produce a stable D9-tetrahydrocannabinol containing inulin-based solid dispersion powder suitable for inhalation. Eur J Pharm Sci 2005;26: 231-40. (Pubitemid 41169806)
20. Mechoulam R. Marihuana chemistry. Science 1970;168: 1159-66.
21. Munjal M, ElSohly MA, Repka MA. Chemical stabilization of a Delta9-Tetrahydrocannabinol prodrug in polymeric matrix systems produced by a hot-melt method: role of microenvironment pH. AAPS PharmSciTech 2006;7:E1-E12.
22. Garrett ER, Hunt A. Physicochemical properties, solubility, and protein binding of D9-tetrahydrocannabinol. J Pharm Sci 1974;63: 1056-64.
23. Jarho P, Pate DW, Brenneisen R, et al. Hydroxypropyl-betacyclodextrin and its combination with hydroxypropyl-methylcellulose increases aqueous solubility of delta9-tetrahydrocannabinol. Life Sci 1998;63:PL381-4.
24. Wilson DM, Peart J, Martin BR, et al. Physiochemical and pharmacological characterization of a D9-THC aerosol generated by a metered dose inhaler. Drug Alcohol Depend 2002;67: 259-67. (Pubitemid 34786261)
25. Hernán Pérez de la Ossa D, Ligresti A, Gil-Alegre ME, et al. Polye- caprolactone microspheres as a drug delivery system for cannabinoid administration: development, characterization and in vitro evaluation of their antitumoral efficacy. J Controlled Release 2012; 161: 927-32.
26. Alexander A, Smith PF, et al. Cannabinoids in the treatment of cancer. Cancer Lett 2009;285: 6-12.
27. Guzmán M, et al. Effects on cell viability. Handb Exp Pharmacol 2005;168: 627-42.
28. Patsos HAHicks DJ, Greenhough A. Cannabinoids and cancer: potential for colorectal cancer therapy. Biochem Soc Trans 2005; 33: 712-14. (Pubitemid 41160846)
29. Ligresti A, Bisogno T, et al. Possible endocannabinoid control of colorectal cancer growth. Gastroenterology 2003;125: 677-87. (Pubitemid 37070686)
30. Caffarel MM, Moreno-Bueno G, Cerutti C, et al. JunD is involved in the antiproliferative effect of [Delta]9-tetrahydrocannabinol on human breast cancer cells. Oncogene 2008;27: 5033-44.
31. Walsh D, Nelson K, Mahmoud F, et al. Established and potential therapeutic applications of cannabinoids in oncology. Support Care Cancer 2003;11: 137-43. (Pubitemid 36733806)
32. Mechoulam R. Chemistry of cannabis. Handbook Exp Pharmacol 1981;55: 119-34.
33. Gill EW, Jones G. Brain levels of D1-THC and its metabolites in mice. Biochem Pharmacol 1972;21: 2237-48.
34. Shi Y, Li LC. Current advances in sustained-release systems for parenteral drug delivery. Expert Opin Drug Deliv 2005;2: 1039-58. (Pubitemid 41701203)
35. Sinha VR, Bansal K, et al. Poly-[epsilon]-caprolactone microspheres and nanospheres: an overview. Int J Pharm 2004;278: 1-23.
36. Li Z, Li Q, Simon S, et al. Formulation of spray-dried phenytoin loaded poly(e-caprolactone) microcarrier intended for brain delivery to treat epilepsy. J Pharm Sci 2007;96: 1018-30. (Pubitemid 46797473)
37. Ligresti A, Moriello AS, Starowicz K, et al. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J Pharmacol Exp Ther 2006;318: 1375-87. (Pubitemid 44268348)
38. Repka MA, Munjal M, ElSohly MA, et al. Temperature stability and bioadhesive properties of delta-9-tetrahydrocannabinol incorporated hydroxypropylcellulose polymer matrix systems. Drug Dev Ind Pharm 2006;32: 21-32. (Pubitemid 43220911)
39. Costa P, Sousa Lobo JM. Modeling and comparison of dissolution profiles. Eur J Pharm Sci 2001;13: 123-33. (Pubitemid 32288781)
40. Barcia E, Herradón C, Herrero-Vanrell R. Biodegradable additives modulate ganciclovir release rate from PLGA microspheres destined to intraocular administration. Lett Drug Design Discov 2005;2: 148-9. (Pubitemid 40388756)
41. Martínez-Sancho C, Herrero-Vanrell R, Negro S. Poly(D,L-lactideco- glycolide) microspheres for long-term intravitreal delivery of aciclovir: influence of fatty and non-fatty additives. J Microencapsul 2003;20: 799-810. (Pubitemid 37406802)
42. Mu L, Feng SS. A novel controlled release formulation for the anticancer drug paclitaxel (Taxol-): PLGA nanoparticles containing vitamin E TPGS. J Controlled Release 2003;86: 33-48. (Pubitemid 35469120)
43. Forrest ML, Won C-Y, Malick AW, et al. In vitro release of the mTOR inhibitor rapamycin from poly(ethylene glycol)-b-poly(Îmcaprolactone) micelles. J Controlled Release 2006;110: 370-7. (Pubitemid 41827491)
44. Menei P, Boisdron-Celle M, Croué A, et al. Effect of stereotactic implantation of biodegradable 5-fluorouracil-loaded microspheres in healthy and C6 glioma-bearing rats. Neurosurgery 1996;39: 117-23.